Abstract
The pathophysiology of degenerative, infectious, inflammatory and traumatic diseases of the central nervous system includes a significant immune component. As to the latter, damage to the cerebral vasculature and neural cell bodies, caused by traumatic brain injury (TBI) activates innate immunity with concomitant infiltration of immunocytes into the damaged nervous system. This leads to proinflammatory cytokine and prostaglandin production and lost synaptic integrity and more generalized neurotoxicity. Engagement of adaptive immune responses follows including the production of antibodies and lymphocyte proliferation. These affect the tempo of disease along with tissue repair and as such provide a number of potential targets for pharmacological treatments for TBI. However, despite a large body of research, no such treatment intervention is currently available. In this review we will discuss the immune response initiated following brain injuries, drawing on knowledge gained from a broad array of experimental and clinical studies. Our discussion seeks to address potential therapeutic targets and propose ways in which the immune system can be controlled to promote neuroprotection.
Keywords: Traumatic brain injury, neuroimmunity, mononuclear phagocytes, astrocytes, neurodegeneration, inflammation.
Current Pharmaceutical Design
Title:Bridge Between Neuroimmunity and Traumatic Brain Injury
Volume: 20 Issue: 26
Author(s): Matthew L. Kelso and Howard E. Gendelman
Affiliation:
Keywords: Traumatic brain injury, neuroimmunity, mononuclear phagocytes, astrocytes, neurodegeneration, inflammation.
Abstract: The pathophysiology of degenerative, infectious, inflammatory and traumatic diseases of the central nervous system includes a significant immune component. As to the latter, damage to the cerebral vasculature and neural cell bodies, caused by traumatic brain injury (TBI) activates innate immunity with concomitant infiltration of immunocytes into the damaged nervous system. This leads to proinflammatory cytokine and prostaglandin production and lost synaptic integrity and more generalized neurotoxicity. Engagement of adaptive immune responses follows including the production of antibodies and lymphocyte proliferation. These affect the tempo of disease along with tissue repair and as such provide a number of potential targets for pharmacological treatments for TBI. However, despite a large body of research, no such treatment intervention is currently available. In this review we will discuss the immune response initiated following brain injuries, drawing on knowledge gained from a broad array of experimental and clinical studies. Our discussion seeks to address potential therapeutic targets and propose ways in which the immune system can be controlled to promote neuroprotection.
Export Options
About this article
Cite this article as:
Kelso L. Matthew and Gendelman E. Howard, Bridge Between Neuroimmunity and Traumatic Brain Injury, Current Pharmaceutical Design 2014; 20 (26) . https://dx.doi.org/10.2174/13816128113196660653
DOI https://dx.doi.org/10.2174/13816128113196660653 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Challenges in the Correct Assessment of a Case of Aggressive Thyroid Carcinoma with Synchronous Breast Cancer: A Case Report and Review of the Literature of Essential Role of Radiopharmaceuticals
Current Radiopharmaceuticals From Antidepressant Drugs to Beta-Mimetics: Preclinical Insights on Potential New Treatments for Neuropathic Pain
Recent Patents on CNS Drug Discovery (Discontinued) Cardiac-Specific Expression of the Hepatocyte Growth Factor (HGF) Under the Control of a TnIc Promoter Confers a Heart Protective Effect After Myocardial Infarction (MI)
Current Gene Therapy Pharmacological Benefits of Active Components of Natural Products Against Traumatic Brain Injury - A Review
Current Pharmacogenomics and Personalized Medicine Bradykinin B2 receptors play a neuroprotective role in Hypoxia/reoxygenation injury related to pyroptosis pathway
Current Neurovascular Research Naturally Occurring Calanolides: An Update on Their Anti-HIV Potential and Total Syntheses
Recent Patents on Biotechnology Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry Conference Report (8th Annual Meeting of the Society for the Study of Neuroprotection and Neuroplasticity)
CNS & Neurological Disorders - Drug Targets Functional Neuroimaging in Memory and Memory Disturbances
Current Medical Imaging Cell Biological Consequences of Mitochondrial NADH: Ubiquinone Oxidoreductase Deficiency
Current Neurovascular Research Treatment of Disorders Characterized by Reversible Airway Obstruction in Childhood: are Anti-cholinergic Agents the Answer?
Current Pharmaceutical Design Current Approaches to Prevention of Contrast Induced Acute Kidney Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry A Case of Neurosarcoidosis Mimicking Brain Tumor
Current Medical Imaging Role of Hexokinase and VDAC in Neurological Disorders
Current Molecular Pharmacology Proteases and Protease-Activated Receptors (PARs): Novel Signals for Pain
Current Topics in Medicinal Chemistry The Multi-faceted Profile of Corticotropin-releasing Factor (CRF) Family of Neuropeptides and of their Receptors on the Paracrine/Local Regulation of the Inflammatory Response
Current Molecular Pharmacology Diabetes and Vascular Disease: Basic Concepts of Nitric Oxide Physiology, Endothelial Dysfunction, Oxidative Stress and Therapeutic Possibilities
Current Vascular Pharmacology Curcumin: Powerful Immunomodulator from Turmeric
Current Immunology Reviews (Discontinued) Polydeoxyribonucleotide (PDRN): A Safe Approach to Induce Therapeutic Angiogenesis in Peripheral Artery Occlusive Disease and in Diabetic Foot Ulcers
Cardiovascular & Hematological Agents in Medicinal Chemistry Nitric Oxide, Peroxynitrite, Peroxynitrous Acid, Nitroxyl, Nitrogen Dioxide, Nitrous Oxide: Biochemical Mechanisms and Bioaction
Current Bioactive Compounds